Iesato Yasuhiro, Imai Akira, Hirano Takao, Toriyama Yuichi, Murata Toshinori
Department of Ophthalmology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Jpn J Ophthalmol. 2016 Mar;60(2):86-94. doi: 10.1007/s10384-016-0425-5. Epub 2016 Jan 22.
To investigate the effect of leaking capillaries and microaneurysms (MAs) in the perifoveal capillary network (PCN) on the treatment of fovea-involving macular edema (ME) secondary to branch retinal vein occlusion (BRVO) by intravitreal ranibizumab (IVR) injections combined with focal, grid, and scatter laser photocoagulation.
Retrospective comparative case series. The MA (+) group consisted of 12 patients with leaking MAs in the PCN and the MA (-) group contained 11 patients without. At 6 months following the initial IVR injection, best corrected visual acuity (BCVA) was evaluated as the primary outcome. Secondary outcomes included central macular thickness (CMT) and the number of IVR injections performed in a pro re nata (PRN) regimen when CMT was ≥300 µm and vision deteriorated by 0.1 logMAR or greater.
Mean BCVA improved by 0.30 ± 0.25 logMAR in the MA (-) group and 0.28 ± 0.20 logMAR in the MA (+) group (both P < 0.0001). Mean CMT was reduced by 237.6 ± 221.4 µm (P < 0.0001) in the MA (-) and 158.2 ± 152.1 µm (P < 0.01) in the MA (+) group. The degrees of improvement in BCVA (P = 0.74) and CMT (P = 0.33) did not vary significantly between the groups. The mean number of additional IVR injections was significantly less in the MA (-) group than in the MA (+) group (2.2 ± 1.0 vs 3.0 ± 0.8; P = 0.04).
Although leaking MAs and capillaries in the PCN did not adversely affect improvements in BCVA and CMT, these manifestations led to an increased number of IVR injections needed to sustain resolution of ME involving the fovea.
探讨黄斑中心凹周围毛细血管网(PCN)中的渗漏性毛细血管和微动脉瘤(MAs)对玻璃体内注射雷珠单抗(IVR)联合局部、格栅和散射激光光凝治疗视网膜分支静脉阻塞(BRVO)继发的累及黄斑中心凹的黄斑水肿(ME)的影响。
回顾性比较病例系列研究。MA(+)组由12例PCN中有渗漏性MAs的患者组成,MA(-)组包含11例无渗漏性MAs的患者。在首次IVR注射后6个月,将最佳矫正视力(BCVA)作为主要结局进行评估。次要结局包括中心黄斑厚度(CMT)以及当CMT≥300 µm且视力下降0.1 logMAR或更多时,按需(PRN)方案中进行的IVR注射次数。
MA(-)组的平均BCVA提高了0.30±0.25 logMAR,MA(+)组提高了0.28±0.20 logMAR(均P<0.0001)。MA(-)组的平均CMT降低了237.6±221.4 µm(P<0.0001),MA(+)组降低了158.2±152.1 µm(P<0.01)。两组之间BCVA(P = 0.74)和CMT(P = 0.33)的改善程度无显著差异。MA(-)组额外IVR注射的平均次数显著少于MA(+)组(2.2±1.0 vs 3.0±0.8;P = 0.04)。
尽管PCN中的渗漏性MAs和毛细血管对BCVA和CMT的改善没有不利影响,但这些表现导致维持累及黄斑中心凹的ME消退所需的IVR注射次数增加。